OMH Osmetech

 

TIDMOMH 
 
RNS Number : 5864Z 
Osmetech PLC 
24 September 2009 
 

                                                                  Osmetech plc 
('Osmetech' or the 'Company') 
Osmetech and Fisher Agree to Terminate US Distribution Agreement 
Osmetech plc ('Osmetech', OMH.L), the international molecular diagnostics 
business, announced today that following discussions with Fisher HealthCare, a 
division of Fisher Scientific Company L.L.C, both companies have mutually agreed 
to terminate, with immediate effect, their US distribution agreement, which was 
entered into in March 2009. 
Osmetech has made the strategic decision to build its own direct sales force in 
the US with the objective of targeting key molecular diagnostic testing 
laboratories as well as clinics that have been established to dose and monitor 
the administration of certain therapeutic drugs. The Company's existing sales 
force, which is currently being expanded, will be further increased over the 
next three years as the molecular testing market grows and more high value tests 
are added to the Company's award winning eSensor XT-8 platform. 
Commenting on this change in sales strategy, President and Chief Executive 
Officer, Faiz Kayyem stated: "We believe that the most effective and profitable 
way for Osmetech to expand placements of our eSensor XT-8 units and associated 
test revenues is to market our products directly in the US through our own 
dedicated sales channel. This sales force will be relatively small in the 
initial phase but structured to allow flexibility in meeting the requirements of 
the dynamic and rapidly expanding molecular diagnostics market. It is our belief 
that the increased control afforded by a direct marketing effort will allow us 
to drive faster growth of our business and create greater value for our 
shareholders. " 
 
 
Osmetech plc                                                               +44 
(0)207 849 6027 
Jon Faiz Kayyem, Chief Executive Officer        +1 626 463 2000 
David Sandilands, Chief Financial Officer 
 
 
Madano Partnership                                                 +44 (0) 207 
593 4000 
Mark Way 
Matthew Moth 
www.madano.com 
 
 
Canacccord Adams Limited                                  +44 (0) 207 050 6500 
Robert Finlay 
Henry Fitzgerald-O'Connor 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGRIIFEEATISFIA 
 

Osmetech (LSE:OMH)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Osmetech (LSE:OMH)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025